[ad_1]
There is still a lack of information
On a European scale, Lithuania also removes drugs from drugs to reduce blood pressure, which contain active ingredients manufactured by the Chinese Zhejiang Company Huahai Pharmaceuticals – Valsartan. It contains carcinogenic impurities.
These drugs are used to treat complications such as myocardial infarction and stroke, and in patients with heart failure or recent myocardial infarction. The generic names of the drugs withdrawn are amlodipine and valsartan, the registered trademarks of amlodipine, Asbima, Suvartar, Tensart, Valsartan, Vanatex, Valzap and Vapress are registered trademarks of the Lithuanian pharmaceutical market.
Valsartan drugs in China were registered by SIA Ingen Pharma, Inteli Generics Nord, UAB, ZENTIVA, Sandoz, EGIS Pharmaceuticals PLC, Actavis Group PTC ehf, SIA Ingen Pharma, ZENTIVA, Medan Pharma SA, Medochemie Ltd.
"I do not know which companies drink blood pressure medications, but valsartan, that's really," says Kristina, a woman who has already done medical education, but in the summer she is less interested by the news of the world and the country. These drugs were on the list. Now, all those who heal for hypertension need to check what they consume.
The Ministry Only Recommends
The National Agency for Drug Control (LPC) announced two weeks ago that the European Medicines Agency (EMA) was reviewing and withdrawing all of these drugs.
The review started after Spain started an emergency withdrawal procedure and shared this information with the other Member States and the European Medicines Agency in the prescribed manner. According to this information, the LHV has also started the process of removing defective drugs from the Lithuanian pharmaceutical network, including pharmacies.
To what extent does the information about this scandal constitute a violation of the rules for the manufacture of generic drugs
? The European Medicines Agency will continue to badess whether impurities pose a risk to patients. Drugs containing impurities have already been removed from the market. The European Medicines Agency will continue to badess whether impurities pose a risk for patients. , drugs in pharmacies are of high quality and usable ", – says Zvidrunas Martynas, deputy chief of the IWC.
Other drugs with this active substance, other than the Chinese Zhejiang Huahai Pharmaceuticals, remain in the pharmacy. Accepts Alina Žilinaitė, spokeswoman for the Ministry of Health, said the treatment can not be stopped and the ministry therefore recommends that pharmacies hand over to other people who have returned to their homes. poor quality
"If a person has taken medications that are removed, they can be brought to any" Amber pharmacy "despite the fact that the package has already started. It will be adopted and replaced by badogues, which is good, "says Rūta Bagdonavičienė, general director of the UAB Gintarinė vaistinė
No matter where and when the return of the drug was purchased, R.Bagdonavičienė considers that & It is an atypical situation, "
" We are talking about health, so we will accept everyone, no matter what drugs are purchased. We will accept and change, and then we will try to explain to the wrong drug manufacturers to compensate for the losses. When a person is sick and consumes drugs, he needs help, treatment continues, so there is no time to delay, something will become clear, "- altruise R.Bagdonavičienė for the profit and loss is much more important in this case the health of the population
"A pharmacy, replacing a mediocre quality drug by an equivalent quality and addressing the cost of cost acquisition , must keep in mind that it is the manufacturer of poor quality drugs who is responsible for the damage and must be compensated. As a result, the pharmacy should cooperate with manufacturers and other suppliers to compensate for losses suffered by pharmaceutical companies ", – comments the representative of the Ministry of Health, A. Zilinait.
According to preliminary calculations of some pharmacies, potentially noncarcinogenic drugs
Kristina Nemaniūtė-Gagė, chairman of the Lithuanian Pharmacy Association, says that pharmacies still do not know what to offer to clients who return the drug.
"We have appealed to the Ministry of Health because certain laws must be adopted to allow pharmacies to change the quality of the product of poor quality. However, the drug is a non-refundable item according to law, and it is not possible to change it, so the intervention of state institutions is necessary ", – said K. Nemaniūtė-Gagė, SNB
Deputy Minister Kristina Garuolienė stressed Friday at a press conference that it was a pan-European problem and that the guidelines on the way to handle this situation was directed by the European Medicines Agency.According to the statement, the pharmacy currently can only accept defective drugs as waste.
The general manager of the SA "Gintarinė vaistinė" R. Bagdonavičienė points out that the production of drugs is subject to a sufficiently strict control and that valsartan is an unprecedented event, which is particularly rare [19659003] Refusal of the right to vote
Ischemic ardiopathies of Kaunas Clinics, Kaunas University, Associate Professor Olivija Gustiene, pointed out that the procedure of compensation and supply of the cheapest drugs is very imperfect. it is clear that the rules for the production of generic drugs have been violated. It's a bad thing that patents – the original pharmaceuticals produced by a pharmaceutical company are almost not reimbursed, pharmacists are pushing for the most affordable drugs for buyers. They are not always the worst, but why are they deprived of their right to choose? Maybe they would prefer a premium, but a patent? Dr. O. Gustiene is disappointed at the moment
Indeed, this scandal on the Valsartan has dealt a blow to generic companies: the Ministry of Health, which regulates the activities of pharmacies and is responsible for the health of the population? What are the conclusions of the European Medicines Agency, which badesses the real risks of impurities.
[ad_2]
Source link
